We are on a mission to redefine cancer care by combining disruptive molecular biology technology with state of the art bioinformatics and machine learning.
Emmanuel, Pangea’s Chief Pharma Alliances, will be meeting both new and existing pharma/biopharma connections at the BIO International Convention in Boston next...
Read More →
ENLIGHT is Pangea’s proprietary tumor intelligence platform
Enabling deeper understanding of how a tumor would respond to therapy. ENLIGHT looks beyond actionable genomic abnormalities by examining the molecular context in which targeted therapies operate. It does so by considering expression abnormalities, which are orders of magnitude more common than actionable mutations - the current staple of precision oncology.
The ENLIGHT platform uncovers several types of functional genetic interactions
Building “gene social networks” that reveal tumor vulnerabilities, our analysis uses multiple measures of activity, including expression, epigenetics, proteomics, and more. Combining these with the tumor vulnerability maps, ENLIGHT uncovers many more clinically relevant insights than approaches based solely on genomic alterations.
Read More
